This article is more than 5 years old. Information may no longer be current.
NEI, Notal Vision launch ancillary study to AREDS2
Click Here to Manage Email Alerts
ST. LOUIS — The National Eye Institute at the U.S. National Institutes of Health has launched an ancillary study to its Age-Related Eye Disease Study 2 comparing the ability of Notal Vision's ForeseeHome age-related macular degeneration monitor to aid the early detection of wet AMD to that of standard care, according to a joint press release from the National Eye Institute and Notal Vision.
The ForeseeHome AMD monitor is the first ophthalmic device to receive U.S. Food and Drug Administration approval for the home monitoring of wet AMD. The device is programmed to transmit eye exam data to the patient's eye care physician, as well as to the Notal Vision Data Monitoring Center, the release said.
AREDS2 is currently evaluating the ability of lutein, zeaxanthin and omega-3 fatty acids for slowing the progression of AMD-linked vision loss among 4,000 patients at moderate to high risk of developing AMD.
Follow OSNSuperSite.com
on Twitter.